Journal · Cancer biology · Updated 19 November 2026
Oncogene
Read Oncogene articles on DeepDyve. No university library needed.
Oncogene has published since 1987 and covers the molecular biology of cancer: the genes, signaling and metabolic changes that drive tumors, and how they might be targeted. Springer Nature publishes it. A DeepDyve subscription lets you read it in full, alongside millions of articles from other journals licensed from publishers including Springer Nature.
Then $59 a month or $499 a year. A credit card is required; cancel during the trial and you won’t be charged. You read articles online; PDFs are sold separately.
Personal plans aren’t for business use. Reading for work? See Enterprise.
Oncogene at a glance
- Full title
- Oncogene
- Abbreviation (NLM)
- Oncogene
- Publisher
- Springer Nature
- Print ISSN
- 0950-9232
- Online ISSN (eISSN)
- 1476-5594
- First published
- 1987
- Subjects
- Molecular Biology, Neoplasms
- Access model
- Hybrid (35% free to read in 2026)
Ways to access Oncogene
35% of the articles Oncogene published from January 1 to November 18, 2026 are open access and free to read. For the rest, look for the authors’ manuscript, check a library, or read them on DeepDyve.
- Open access articles. 35% of Oncogene articles published from January 1 to November 18, 2026 carry a Creative Commons license, per Crossref, and are free to read. They’re marked “Open access” below.
- The authors’ accepted manuscript. For subscription articles, Springer Nature lets authors make their accepted manuscript public 6 months after publication, on a personal website or in a repository such as PubMed Central.
- NIH-funded research. For papers accepted on or after July 1, 2025, the US National Institutes of Health requires the accepted manuscript in PubMed Central, free with no embargo from the official publication date.
- A library. Your university, hospital or public library may subscribe to Oncogene. Check its journal list and whether it offers remote access.
- DeepDyve. Read Oncogene articles online for $59 a month or $499 a year after a free first month. Articles marked LitStream below are in DeepDyve’s LitStream collection, which a subscription lets you read online. PDFs are sold separately, and availability varies by article.
Sources: Springer Nature self-archiving policy; NIH Public Access Policy; open access share from Crossref license data.
Recent Oncogene research worth reading
Published February to June 2026. Summaries describe what the authors report.
-
Cancer-associated fibroblasts as key regulators of lipid metabolism in the tumour microenvironment
The authors review how cancer-associated fibroblasts produce, secrete, take up and break down lipids in tumors, note that their role in lipid metabolism appears to differ between cancer types, and consider how this affects tumor progression and treatment resistance.
Adams et al. · Oncogene, published online March 21, 2026 · DOI 10.1038/s41388-026-03733-9
-
METTL1-mediated m7G modification of ASNS mRNA regulates asparagine metabolism reprogramming to promote hepatocellular carcinoma progression
Xing and colleagues report that METTL1 is upregulated in hepatocellular carcinoma tissue and linked to advanced stage and poor survival, and that it stabilizes ASNS mRNA through m7G modification, reprogramming asparagine metabolism and activating mTOR signaling to promote tumor progression.
Xing et al. · Oncogene, published online April 27, 2026 · DOI 10.1038/s41388-026-03806-9
-
The deubiquitinase USP17 regulates the expression and activity of the oncogenic driver β-catenin in colorectal cancer
Acevedo and colleagues report that the deubiquitinase USP17 binds and stabilizes β-catenin in colorectal cancer cells, and that depleting it reduced β-catenin levels, epithelial-mesenchymal transition and cell proliferation and impaired tumor growth in vivo.
Acevedo et al. · Oncogene, published online February 19, 2026 · DOI 10.1038/s41388-026-03695-y
-
Intratumoral bicarbonate functions as an adjuvant to potentiate PD-1 blockade in hepatocellular carcinoma
Wang and colleagues report that injecting sodium bicarbonate into tumors enhanced PD-1 blockade in mouse models of hepatocellular carcinoma, and that in a prospective study of 28 advanced-stage and 2 intermediate-stage patients given tislelizumab plus intratumoral bicarbonate, the objective response rate was 93.3%.
Wang et al. · Oncogene, published online June 5, 2026 · DOI 10.1038/s41388-026-03836-3
-
ZDHHC9-mediated KLF5 palmitoylation enhances the cAMP/PKA/CREB axis to promote colorectal cancer progression
Zhang and colleagues report that the palmitoyl transferase ZDHHC9 is upregulated in colorectal cancer and linked to poor prognosis, and that it palmitoylates KLF5 at cysteine 438, raising cAMP/PKA/CREB signaling that drives cancer cell proliferation and migration.
Zhang et al. · Oncogene, published online March 25, 2026 · DOI 10.1038/s41388-026-03724-w
Related journals
Questions about Oncogene
How can I read Oncogene articles without a subscription?
35% of Oncogene articles published from January 1 to November 18, 2026 are open access and free to read. For subscription articles, Springer Nature lets authors make their accepted manuscript public 6 months after publication, on a personal website or in a repository such as PubMed Central. Your library may also subscribe. DeepDyve lets you read Oncogene articles online for $59 a month or $499 a year after a free first month.
What is the abbreviation for Oncogene?
Oncogene isn’t abbreviated: its NLM (PubMed) abbreviation is simply Oncogene.
What is the ISSN of Oncogene?
The print ISSN is 0950-9232 and the online ISSN is 1476-5594.
Is Oncogene open access?
Oncogene is a hybrid journal: most articles are published under the subscription model, and authors can choose to publish open access. From January 1 to November 18, 2026, 118 of 338 Oncogene articles (35%) carry a Creative Commons license, per Crossref.
Oncogene articles on DeepDyve are licensed from Springer Nature. Journal facts as of 19 November 2026.
Start reading Oncogene today
One month free, then less than $2 a day. Oncogene, plus millions of articles from thousands of journals.




